Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Market Access Risk Assessment Company - MARA Rating Company

MARA Rating™ — Independent Reimbursement Risk Signal

Pembrolizumab

A structured, committee-based reimbursement risk signal of Pembrolizumab grounded in historical payer decisions — before pricing, negotiation, or launch capital is committed.
Reimbursement risk follows observable patterns tied to evidence strength, comparators, and payer decision thresholds. The MARA Rating® of Pembrolizumab captures these patterns through a calibrated, committee-reviewed assessment and translates them into a clear, comparable grade.

Your browser does not support embedded PDFs. Download the PDF.

What This MARA Rating Signals

A MARA rating is  not a forecast or projection.


It is a standardized risk signal based on calibrated analysis of historical payer behavior across comparable evidence profiles.

Grades in this range have historically aligned with:

  • Defined patterns of HTA scrutiny

  • Predictable pricing negotiation pressure points

  • Specific evidence-sensitivity profiles

  • Distinct reimbursement breadth outcomes

The Full Report provides:

  • Which variables most influenced this grade

  • Structured interpretation of how similar ratings translated to reimbursement outcomes

  • Where mitigation effort can change the trajectory

 

Because a grade alone is a signal. Interpretation determines strategy.

Why This Matters Before Pricing and Launch

This Full MARA Reimbursement Risk Assessment is designed to provide a defensible internal benchmark prior to major capital commitments in pricing, evidence generation, partnership decisions, or launch planning.

 

Who Uses MARA Reports

MARA Reports are typically used by:
• Market Access and HEOR leaders requiring a standardized benchmark
• Business Development teams evaluating portfolio and deal risk
• Portfolio strategy and investment committees assessing reimbursement exposure
• Life-sciences investors incorporating independent access risk signals

 

MARA exists to reduce blind exposure before those decisions are locked in.

Know before you go.

What you are purchasing

Full MARA Reimbursement Risk Assessment — Internal Use License

Includes:

  • Structured breakdown across HTA-aligned domains

  • Variable-level scoring and heatmap interpretation

  • Cross-asset benchmarking within therapeutic area

  • Context from comparable historical decisions

  • Practical implications for pricing and negotiation strategy

  • One-time internal organizational license.*

Designed for decision preparation — not retrospective analysis.

CHF 3,490 — One-Time Internal License

*External display or public presentation of the MARA Rating® requires a separate Display License. Internal organizational use is covered by the Internal Use License.

Understand What This Grade Really Means

The Full MARA Report provides:

  • Decision-critical variable breakdown

  • Peer benchmarking across comparable assets

  • Interpretation of what similar grades achieved in real reimbursement outcomes

  • Clear view of where to focus resources 

     

CHF 3,490 — One-Time Internal License

  • Before pricing assumptions are locked in.
  • Before launch budgets are approved.